Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat


Tytuł :
The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.
Autorzy :
Choi SY; Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea.
Lim B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Chi BH; Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea.
Lee W; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Kim JH; Department of Urology, Hanil General Hospital, Seoul, Republic of Korea.
Kyung YS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
You D; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Kim CS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Aug 06; Vol. 100 (31), pp. e26833.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatectomy*/adverse effects
Prostatectomy*/methods
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/mortality
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/therapy
Radiotherapy*/adverse effects
Radiotherapy*/methods
Androgen Antagonists/*therapeutic use
Aged ; Biomarkers, Tumor/blood ; Combined Modality Therapy/methods ; Humans ; Kaplan-Meier Estimate ; Male ; Neoplasm Staging ; Outcome and Process Assessment, Health Care ; Patient Selection ; Proportional Hazards Models ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/epidemiology ; Republic of Korea/epidemiology ; Risk Assessment
Czasopismo naukowe
Tytuł :
MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer.
Autorzy :
Kalogirou C; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Linxweiler J; Department of Urology, Saarland University, Homburg/Saar, Germany.
Schmucker P; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Snaebjornsson MT; German Cancer Research Center, Division of Tumor Metabolism and Microenvironment, Heidelberg, Germany.
Schmitz W; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.
Wach S; Department of Urology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Krebs M; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Hartmann E; Institute of Pathology, Julius Maximilians University and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany.
Puhr M; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Müller A; Clinic for Diagnostic and Interventional Radiology, Saarland University, Homburg/Saar, Germany.
Spahn M; Center for Urology, Hirslanden Private Hospital Group, Zurich, Switzerland.
Seitz AK; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Frank T; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Marouf H; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.
Büchel G; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.; Mildred Scheel Early Career Center, University Hospital Würzburg, Würzburg, Germany.
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Kübler H; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Eilers M; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.
Saar M; Department of Urology, Saarland University, Homburg/Saar, Germany.
Junker K; Department of Urology, Saarland University, Homburg/Saar, Germany.
Röhrig F; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany.
Kneitz B; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Rosenfeldt MT; Institute of Pathology, Julius Maximilians University and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany.
Schulze A; Department of Biochemistry and Molecular Biology, Theodor-Boveri-Institute, Biocenter, Würzburg, Germany. .; German Cancer Research Center, Division of Tumor Metabolism and Microenvironment, Heidelberg, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Aug 20; Vol. 12 (1), pp. 5066. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Cholesterol/*biosynthesis
Down-Regulation/*genetics
MicroRNAs/*metabolism
Prostatic Neoplasms/*drug therapy
Prostatic Neoplasms/*genetics
Squalene Monooxygenase/*antagonists & inhibitors
Aged ; Aged, 80 and over ; Animals ; Base Sequence ; Cell Line, Tumor ; Cell Proliferation/genetics ; Cell Survival ; Cohort Studies ; Computer Simulation ; Disease Models, Animal ; Drug Resistance, Neoplasm/genetics ; Humans ; Male ; Mice ; Mice, SCID ; MicroRNAs/genetics ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Neoplasm Staging ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/metabolism ; Squalene Monooxygenase/genetics ; Squalene Monooxygenase/metabolism ; Terbinafine/pharmacology ; Transcriptional Activation/genetics
Czasopismo naukowe
Tytuł :
Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Autorzy :
Schiewer MJ; Department of Urology, Urology Research Laboratory, Thomas Jefferson University, Sidney Kimmel Cancer Center, 233 South 10th Street BLSB 804, Philadelphia, PA 19107, USA; Department of Cancer Biology, Urology Research Laboratory, Thomas Jefferson University, Sidney Kimmel Cancer Center, 233 South 10th Street BLSB 804, Philadelphia, PA 19107, USA. Electronic address: .
Knudsen KE; Department of Cancer Biology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Urology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Medical Oncology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Radiation Oncology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA. Electronic address: https://twitter.com/SKCCDirector.
Pokaż więcej
Źródło :
The Urologic clinics of North America [Urol Clin North Am] 2021 Aug; Vol. 48 (3), pp. 339-347. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*pathology
Receptors, Androgen/*genetics
Androgen Antagonists/therapeutic use ; Biomarkers, Tumor/genetics ; Cell Plasticity ; DNA Repair ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Genetic Testing ; Germ-Line Mutation ; Humans ; Male ; Precision Medicine ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology
Czasopismo naukowe
Tytuł :
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Autorzy :
Wu MJ; Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan.
Chen CJ; Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, 40201, Taiwan.
Lin TY; Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan.
Liu YY; Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan.
Tseng LL; Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan.
Cheng ML; Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Chuu CP; Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan.
Tsai HK; Institute of Information Science, Academia Sinica, Taipei, 11529, Taiwan.
Kuo WL; Division of Breast Surgery, General Surgery, Department of Surgery, Chang Gung Memorial Hospital Linko Medical Center, Taoyuan 333, Taiwan.
Kung HJ; Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 110, Taiwan.; Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, University of California Davis Cancer Centre, Sacramento, CA 95817, USA.
Wang WC; Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan.
Pokaż więcej
Źródło :
Theranostics [Theranostics] 2021 Jun 26; Vol. 11 (16), pp. 7779-7796. Date of Electronic Publication: 2021 Jun 26 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Jumonji Domain-Containing Histone Demethylases/*metabolism
Prostatic Neoplasms, Castration-Resistant/*metabolism
Androgen Antagonists ; Animals ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Heterografts ; Humans ; Jumonji Domain-Containing Histone Demethylases/physiology ; Male ; Mice, Inbred BALB C ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/metabolism ; Signal Transduction/genetics ; Transcription Factors/metabolism
Czasopismo naukowe
Tytuł :
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Autorzy :
González Del Alba A; Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Joaquin Rodrigo 2, Majadahonda, 28222, Madrid, Spain. .
Méndez-Vidal MJ; Medical Oncology Department, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain.
Vazquez S; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Castro E; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional de Mälaga, Málaga, Spain.
Climent MA; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, València, Spain.
Gallardo E; Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.
Gonzalez-Billalabeitia E; Medical Oncology Department, Hospital Universitario Doce de Octubre, Instituto Imas12, Madrid, Spain.; Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain.
Lorente D; Medical Oncology Department, Hospital Provincial de Castellón, Castellon, Spain.
Maroto JP; Medical Oncology Department, Hospital Universitari Santa Creu i San Pau, Barcelona, Spain.
Arranz JA; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Pokaż więcej
Źródło :
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 May; Vol. 23 (5), pp. 969-979. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Journal Article
MeSH Terms :
Androgen Antagonists/*therapeutic use
Antineoplastic Agents/*therapeutic use
Prostatic Neoplasms/*therapy
Androstenes/therapeutic use ; Benzamides/therapeutic use ; Combined Modality Therapy/methods ; Docetaxel/therapeutic use ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic Testing/methods ; Humans ; Male ; Medical Oncology ; Nitriles/therapeutic use ; Orchiectomy ; Phenylthiohydantoin/therapeutic use ; Phthalazines/therapeutic use ; Piperazines/therapeutic use ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/therapy ; Radiotherapy/methods ; Randomized Controlled Trials as Topic ; Societies, Medical ; Spain ; Thiohydantoins/therapeutic use
Czasopismo naukowe
Tytuł :
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Autorzy :
Fan L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fei X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhu Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pan J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Sha J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chi C; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gong Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Du X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhou L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dong B; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xue W; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Feb; Vol. 205 (2), pp. 461-469. Date of Electronic Publication: 2020 Sep 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sequence Analysis, DNA*
Circulating Tumor DNA/*blood
Circulating Tumor DNA/*genetics
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*genetics
Aged ; Androgen Antagonists/therapeutic use ; Genomics ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Autorzy :
Svensson J; Astellas Pharma a/s - Nordic Operations, Kastrup, Denmark.
Lissbrant IF; Department of Oncology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
Gauffin O; Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Hjälm-Eriksson M; Department of Oncology and Pathology, Capio St. Göran's Hospital, Karolinska Institute, Stockholm, Sweden.
Kilany S; Astellas Pharma a/s - Nordic Operations, Kastrup, Denmark.
Fagerlund K; Astellas Pharma a/s - Nordic Operations, Kastrup, Denmark.
Stattin P; Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Pokaż więcej
Źródło :
Scandinavian journal of urology [Scand J Urol] 2021 Feb; Vol. 55 (1), pp. 1-8. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Journal Article
MeSH Terms :
Cost of Illness*
Duration of Therapy*
Prostatic Neoplasms/*economics
Prostatic Neoplasms/*therapy
Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Pilot Projects ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/economics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Registries ; Sweden
Czasopismo naukowe
Tytuł :
Genomic and phenotypic heterogeneity in prostate cancer.
Autorzy :
Haffner MC; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Pathology, University of Washington, Seattle, WA, USA. .; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .
Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Roudier MP; Department of Urology, University of Washington, Seattle, WA, USA.
True LD; Department of Pathology, University of Washington, Seattle, WA, USA.
Nelson WG; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Epstein JI; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
De Marzo AM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nelson PS; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Yegnasubramanian S; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło :
Nature reviews. Urology [Nat Rev Urol] 2021 Feb; Vol. 18 (2), pp. 79-92. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
MeSH Terms :
Genetic Heterogeneity*
Phenotype*
Neoplasms, Multiple Primary/*genetics
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*pathology
Biomarkers, Tumor/blood ; Epigenesis, Genetic ; Genome ; Genomics ; Humans ; Male ; Neoplasm Metastasis/genetics ; Neoplasms, Multiple Primary/pathology ; Prostatic Neoplasms/therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Autorzy :
Xu MC; Vanderbilt University School of Medicine, Nashville, Tennessee.
Huelster HL; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Hatcher JB; Vanderbilt University School of Medicine, Nashville, Tennessee.
Avulova S; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Stocks BT; Vanderbilt University School of Medicine, Nashville, Tennessee.
Glaser ZA; Vanderbilt University School of Medicine, Nashville, Tennessee.
Moses KA; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Silver HJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Mar; Vol. 205 (3), pp. 800-805. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Obesity/*complications
Prostatic Neoplasms/*pathology
Sarcopenia/*complications
Adipose Tissue/diagnostic imaging ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Muscle, Skeletal/diagnostic imaging ; Neoplasm Metastasis ; Neoplasm Staging ; Obesity/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Sarcopenia/diagnostic imaging ; Survival Rate ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Autorzy :
Fersino S; Radiation Oncology Department, Azienda Provinciale per i Servizi Sanitari, Ospedale S.Chiara, Largo Medaglie d'oro, 9, 38122, Trento, Italy. .
Borghesi S; Radiotherapy Unit- Ospedale S. Donato e Santa Maria alla Gruccia, Azienda USL Toscana Sud, Arezzo, Italy.
Jereczek-Fossa BA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Arcangeli S; UOC Radioterapia ASST Monza, Università di Milano, Bicocca, Italy.
Mortellaro G; Department of Radiation Oncology, ARNAS Ospedale Civico, Palermo, Italy.
Magrini SM; Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Alongi F; Advanced Radiation Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar-Verona, Italy.; University of Brescia, Brescia, Italy.
Pokaż więcej
Corporate Authors :
Uro-Oncology study group of Italian association of Radiotherapy and Clinical Oncology (AIRO)
Źródło :
La Radiologia medica [Radiol Med] 2021 Mar; Vol. 126 (3), pp. 460-465. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Journal Article
MeSH Terms :
Attitude of Health Personnel*
Radiation Oncologists*
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Health Care Surveys/*statistics & numerical data
Prostatic Neoplasms/*drug therapy
Androstenes/therapeutic use ; Combined Modality Therapy/methods ; Gonadotropin-Releasing Hormone/agonists ; Humans ; Italy ; Male ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatectomy ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/radiotherapy ; Risk Factors ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł :
Treating Prostate Cancer by Antibody-Drug Conjugates.
Autorzy :
Rosellini M; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Santoni M; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Mollica V; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Rizzo A; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Cimadamore A; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Scarpelli M; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Storti N; Direzione Sanitaria Azienda Sanitaria Unica Regionale, 60122 Ancona, Italy.
Battelli N; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Montironi R; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Massari F; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 04; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Immunoconjugates/*therapeutic use
Prostatic Neoplasms/*drug therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Biomarkers, Tumor ; Clinical Trials as Topic ; Disease Management ; Disease Susceptibility ; Humans ; Immunoconjugates/pharmacology ; Male ; Molecular Targeted Therapy ; Prognosis ; Prostatic Neoplasms/etiology ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/etiology ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Standard of Care ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer.
Autorzy :
Aizawa R; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan.
Takayama K; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan; Department of Radiology, Tenri Hospital, Tenri-shi, Nara, Japan.
Nakamura K; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan.
Inoue T; Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto Japan; Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Yamasaki T; Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto Japan.
Kobayashi T; Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto Japan.
Akamatsu S; Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto Japan.
Ogawa O; Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto Japan.
Mizowaki T; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan. Electronic address: .
Pokaż więcej
Źródło :
Urologic oncology [Urol Oncol] 2021 Feb; Vol. 39 (2), pp. 131.e9-131.e15. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Radiotherapy, Intensity-Modulated*
Prostatic Neoplasms/*radiotherapy
Age Factors ; Aged ; Disease Progression ; Humans ; Male ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/epidemiology ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms, Castration-Resistant/epidemiology ; Retrospective Studies ; Risk Assessment
Czasopismo naukowe
Tytuł :
Contemporary management of advanced prostate cancer: an evolving landscape.
Autorzy :
Khanna A; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
O'Connor LP; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Murthy PB; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Bryk DJ; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Fascelli M; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Ericson K; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Yerram NK; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Haywood SC; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Abouassaly R; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Pokaż więcej
Źródło :
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2021 Feb; Vol. 19 (2), pp. 108-118.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Therapies, Investigational*
Adenocarcinoma/*therapy
Prostatic Neoplasms/*therapy
Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/secondary ; Androstenes/therapeutic use ; Benzamides/therapeutic use ; Clinical Trials as Topic ; Combined Modality Therapy ; Diagnostic Imaging/methods ; Disease Management ; Docetaxel/therapeutic use ; Humans ; Male ; Multicenter Studies as Topic ; Nitriles/therapeutic use ; Phenylthiohydantoin/therapeutic use ; Precision Medicine ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/therapy ; Radiotherapy, Adjuvant ; Radium/therapeutic use ; Taxoids/therapeutic use
Czasopismo naukowe
Tytuł :
Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Autorzy :
Zhang Y; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Chen B; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Xu N; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Xu P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Lin W; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Liu C; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Huang P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Jan 12; Vol. 16, pp. 315-327. Date of Electronic Publication: 2021 Jan 12 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Androgens/*pharmacology
Exosomes/*metabolism
Heme Oxygenase-1/*metabolism
Prostatic Neoplasms/*pathology
Up-Regulation/*drug effects
Animals ; Cell Line, Tumor ; Disease Progression ; Exosomes/ultrastructure ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice, Inbred NOD ; Mice, SCID ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
4,4'-Diisothiocyanatostilbene-2,2'-disulfonate modulates voltage-gated K current and influences cell cycle arrest in androgen sensitive and insensitive human prostate cancer cell lines.
Autorzy :
George K; Department of Biomedical Engineering, Chennai Institute of Technology, Chennai, India.; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Thomas NS; Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, India.
Malathi R; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Pokaż więcej
Źródło :
Toxicology mechanisms and methods [Toxicol Mech Methods] 2020 Jun; Vol. 30 (5), pp. 358-369. Date of Electronic Publication: 2020 Apr 01.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/*pharmacology
Antineoplastic Agents/*pharmacology
Cell Cycle Checkpoints/*drug effects
Potassium Channel Blockers/*pharmacology
Potassium Channels, Voltage-Gated/*antagonists & inhibitors
Receptors, Androgen/*metabolism
Apoptosis/drug effects ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Humans ; Male ; Membrane Potentials/drug effects ; PC-3 Cells ; Patch-Clamp Techniques ; Potassium Channels, Voltage-Gated/metabolism ; Prostate/drug effects ; Prostate/metabolism ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Tetraethylammonium/pharmacology
Czasopismo naukowe
Tytuł :
Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Autorzy :
Fan L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fei X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhu Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chi C; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pan J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Sha J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xin Z; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gong Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Du X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wang Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dong B; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xue W; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 630-637. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Carboplatin/*therapeutic use
Cisplatin/*therapeutic use
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Ataxia Telangiectasia Mutated Proteins/genetics ; BRCA2 Protein/genetics ; Biopsy ; Carboplatin/pharmacology ; Cisplatin/pharmacology ; Cyclin-Dependent Kinases/genetics ; DNA Mutational Analysis ; Docetaxel/pharmacology ; Docetaxel/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Homologous Recombination/genetics ; Humans ; Kallikreins/blood ; Male ; Middle Aged ; Mutation ; Progression-Free Survival ; Prostate/pathology ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/secondary ; Retrospective Studies
Czasopismo naukowe
Tytuł :
The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Autorzy :
Rajwa P; Department of Urology, Medical University of Vienna, Vienna, Austria.; Department of Urology, Medical University of Silesia, Zabrze, Poland.
Mori K; Department of Urology, Medical University of Vienna, Vienna, Austria.; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Huebner NA; Department of Urology, Medical University of Vienna, Vienna, Austria.; Working Group for Diagnostic Imaging in Urology, Austrian Association of Urology, Vienna, Austria.
Martin DT; Department of Urology, Yale School of Medicine, New Haven, Connecticut.
Sprenkle PC; Department of Urology, Yale School of Medicine, New Haven, Connecticut.
Weinreb JC; Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut.
Ploussard G; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
Pradere B; Department of Urology, Medical University of Vienna, Vienna, Austria.
Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.; Department of Urology, Weill Cornell Medical College, New York, New York.; Department of Urology, University of Texas Southwestern, Dallas, Texas.; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Leapman MS; Department of Urology, Yale School of Medicine, New Haven, Connecticut.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 507-516. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Magnetic Resonance Imaging*
Kallikreins/*blood
Neoplasm Recurrence, Local/*epidemiology
Prostate/*diagnostic imaging
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*therapy
Brachytherapy ; Humans ; Male ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/prevention & control ; Prognosis ; Prostate/radiation effects ; Prostate/surgery ; Prostatectomy ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/epidemiology ; Risk Assessment/methods
Czasopismo naukowe
Tytuł :
Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers.
Autorzy :
Chin JL; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Lavi A; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Metcalfe MJ; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Siddiqui K; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Dewar M; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Petros FG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Li R; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nogueras González GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nair SM; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Ward JF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pisters L; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 646-654. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms :
Cryosurgery/*adverse effects
Neoadjuvant Therapy/*methods
Neoplasm Recurrence, Local/*therapy
Postoperative Complications/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*therapy
Salvage Therapy/*adverse effects
Aged ; Androgen Antagonists/pharmacology ; Androgen Antagonists/therapeutic use ; Chemotherapy, Adjuvant/statistics & numerical data ; Follow-Up Studies ; Humans ; Kallikreins/blood ; Male ; Neoadjuvant Therapy/statistics & numerical data ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/mortality ; Postoperative Complications/etiology ; Prospective Studies ; Prostate/pathology ; Prostate/radiation effects ; Prostate/surgery ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/mortality ; Radiation Tolerance ; Radiotherapy, Adjuvant/statistics & numerical data ; Retrospective Studies ; Salvage Therapy/methods ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
Autorzy :
Raman AG; Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Sarma KV; Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Raman SS; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Priester AM; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Bioengineering, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Mirak SA; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Riskin-Jones HH; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Dhinagar N; Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Speier W; Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Felker E; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Sisk AE; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Lu D; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Kinnaird A; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Reiter RE; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Marks LS; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Arnold CW; Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Bioengineering, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 595-603. Date of Electronic Publication: 2021 Apr 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Multimodal Imaging/*methods
Prostate/*pathology
Prostatectomy/*statistics & numerical data
Prostatic Neoplasms/*diagnosis
Aged ; Biopsy, Large-Core Needle/methods ; Biopsy, Large-Core Needle/statistics & numerical data ; Datasets as Topic ; Feasibility Studies ; Humans ; Image-Guided Biopsy/methods ; Image-Guided Biopsy/statistics & numerical data ; Magnetic Resonance Imaging, Interventional/methods ; Magnetic Resonance Imaging, Interventional/statistics & numerical data ; Male ; Middle Aged ; Multimodal Imaging/statistics & numerical data ; Multiparametric Magnetic Resonance Imaging/statistics & numerical data ; Neoplasm Grading ; Prostate/diagnostic imaging ; Prostate/surgery ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Retrospective Studies ; Spatial Analysis ; Ultrasonography, Interventional/statistics & numerical data
Czasopismo naukowe
Tytuł :
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Autorzy :
Marshall CH; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands.
Chen Y; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.
Kuo C; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.
Cullen J; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Marylands.
Jiang J; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Marylands.
Rosner I; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.
Markowski M; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands.
McLeod DG; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.
Trock BJ; Department of Urology, Johns Hopkins School of Medicine, Baltimore, Marylands.
Eisenberger MA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 623-629. Date of Electronic Publication: 2021 May 18.
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Androgen Antagonists/*therapeutic use
Kallikreins/*blood
Neoplasm Recurrence, Local/*drug therapy
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*therapy
Time-to-Treatment/*statistics & numerical data
Aged ; Chemotherapy, Adjuvant/methods ; Clinical Decision-Making ; Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/epidemiology ; Practice Guidelines as Topic ; Prostate/pathology ; Prostate/surgery ; Prostatectomy ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/mortality ; Retrospective Studies ; Time Factors ; Time-to-Treatment/standards
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies